Zacks Small Cap Research on MSN27m
BLRX: 2024 Financial ResultsBLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ:BLRX) reported full-year 2024 results, with revenues reaching $28.9 million. As the company completes its commercialization transition of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback